Denali Therapeutics (NASDAQ:DNLI) Price Target Raised to $34.00

Denali Therapeutics (NASDAQ:DNLI) had its price objective boosted by equities research analysts at Robert W. Baird from $32.00 to $34.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Robert W. Baird’s target price points to a potential upside of 75.44% from the company’s previous close.

Several other research analysts have also recently weighed in on the stock. BTIG Research boosted their price target on shares of Denali Therapeutics from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, March 25th. UBS Group began coverage on shares of Denali Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating on the stock. Jefferies Financial Group restated a “buy” rating and set a $40.00 price target on shares of Denali Therapeutics in a report on Monday, March 2nd. Wedbush cut their price target on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, December 11th. Finally, Morgan Stanley boosted their price target on shares of Denali Therapeutics from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Denali Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Denali Therapeutics Trading Down 6.2%

NASDAQ:DNLI opened at $19.38 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.16 and a quick ratio of 9.16. The firm has a 50-day moving average of $20.46 and a 200-day moving average of $18.12. The company has a market cap of $3.07 billion, a PE ratio of -6.53 and a beta of 1.10. Denali Therapeutics has a one year low of $10.57 and a one year high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same quarter in the prior year, the company earned ($0.67) EPS. As a group, equities research analysts expect that Denali Therapeutics will post -2.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Foresite Capital Management VI LLC bought a new position in shares of Denali Therapeutics during the 3rd quarter valued at approximately $14,520,000. AlphaQuest LLC grew its position in shares of Denali Therapeutics by 224.1% during the 3rd quarter. AlphaQuest LLC now owns 74,422 shares of the company’s stock valued at $1,081,000 after acquiring an additional 51,458 shares during the period. Aberdeen Group plc grew its position in shares of Denali Therapeutics by 23.4% during the 3rd quarter. Aberdeen Group plc now owns 1,113,586 shares of the company’s stock valued at $16,169,000 after acquiring an additional 210,835 shares during the period. Principal Financial Group Inc. grew its position in shares of Denali Therapeutics by 18.5% during the 3rd quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company’s stock valued at $18,458,000 after acquiring an additional 198,207 shares during the period. Finally, Holocene Advisors LP grew its position in shares of Denali Therapeutics by 677.8% during the 3rd quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock valued at $45,531,000 after acquiring an additional 2,732,540 shares during the period. 92.92% of the stock is owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.